Aurobindo Pharma subsidiary's plant gets one observation from USFDA

"At the end of the inspection, Aurolife has been issued a 'Form 483' with 1 observation and the observation is procedural in nature and there are no data integrity issues," Aurobindo Pharma said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RUkyZdm
via IFTTT